Evidence map›Paper›PMID 26350498›Full record

ArticleScientific reports2015

BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor.

Yi Fu, Guoqiang Yu, Douglas A Levine, Niya Wang, Ie-Ming Shih, Zhen Zhang, Robert Clarke, Yue Wang

Abstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Frontiers in genetics · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yi FuDepartment of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 22203, USA.
Guoqiang YuDepartment of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 22203, USA.
Douglas A LevineDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Niya WangDepartment of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 22203, USA.
Ie-Ming ShihDepartments of Pathology and Oncology, Johns Hopkins University, Baltimore, MD 21231, USA.
Zhen ZhangDepartments of Pathology and Oncology, Johns Hopkins University, Baltimore, MD 21231, USA.
Robert ClarkeLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Yue WangDepartment of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 22203, USA.

Funding

Genomic and Proteomic Architecture of AtherosclerosisR01HL111362 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HERRINGTON, DAVID MCLEOD · 2012 to 2021
$17.2M
Proteome Characterization Center: A Genoproteomics Pipeline for Cance ResearchU24CA160036 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2011 to 2016
$10.7M
Improved Diagnostic of the Muscular DystrophiesR01NS029525 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOFFMAN, ERIC P. · 1991 to 2015
$6.5M
Collaborative Research in Integrative Cancer BiologyU01CA184902 · NCI · GEORGETOWN UNIVERSITY · PI CLARKE, ROBERT R., WANG, YUE · 2014 to 2018
$2.7M
Uncovering Estrogen Receptor-Signaling Networks to Overcome Endocrine ResistanceR01CA149653 · NCI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI XUAN, JASON JIANHUA · 2011 to 2015
$1.5M
Integrating epigenomic maps to predict regulatory functions of genetic variantsR01ES024988 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LIU, CHUNYU · 2014 to 2015
$625k
NCI NIH HHS CA149653NCI NIH HHS CA160036NCI NIH HHS CA184902NCI NIH HHS R01 CA149653NCI NIH HHS U01 CA184902NCI NIH HHS U24 CA160036NHLBI NIH HHS HL111362NHLBI NIH HHS R01 HL111362NIEHS NIH HHS ES024988NIEHS NIH HHS R01 ES024988NINDS NIH HHS NS029525NINDS NIH HHS R01 NS029525
6 · The paper itself

Abstract

Most published copy number datasets on solid tumors were obtained from specimens comprised of mixed cell populations, for which the varying tumor-stroma proportions are unknown or unreported. The inability to correct for signal mixing represents a major limitation on the use of these datasets for subsequent analyses, such as discerning deletion types or detecting driver aberrations. We describe the BACOM2.0 method with enhanced accuracy and functionality to normalize copy number signals, detect deletion types, estimate tumor purity, quantify true copy numbers, and calculate average-ploidy value. While BACOM has been validated and used with promising results, subsequent BACOM analysis of the TCGA ovarian cancer dataset found that the estimated average tumor purity was lower than expected. In this report, we first show that this lowered estimate of tumor purity is the combined result of imprecise signal normalization and parameter estimation. Then, we describe effective allele-specific absolute normalization and quantification methods that can enhance BACOM applications in many biological contexts while in the presence of various confounders. Finally, we discuss the advantages of BACOM in relation to alternative approaches. Here we detail this revised computational approach, BACOM2.0, and validate its performance in real and simulated datasets.

Indexed as

DNA Copy Number VariationsGene DosageSoftwareAllelesComputational BiologyFemaleGenomicsHumansNeoplasmsOvarian NeoplasmsWeb Browser

Identifiers

PMID26350498
PMCPMC4563570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.